Atara Biotherapeutics Inc
NASDAQ:ATRA
| Market Cap (Intraday) | 1.44B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $16.39 |
| 50-Day MA | $14.04 |
| 200-Day MA | $15.90 |
Atara Biotherapeutics Inc Stock, NASDAQ:ATRA
611 Gateway Boulevard, Suite 900, South San Francisco, California 94080
United States of America
Phone: +1.650.278.8930
Number of Employees: 437
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.